Skip to main content
OpenTrials
Completed

NCT Number: NCT04629300

Supportive Care Mobile Application for Patients With NSCLC

This research study is looking at the role of a supportive care mobile app in improving symptoms, coping skills, and quality of life in patients with non-small cell lung cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non Small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Coping Skills Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Quality of Life Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Loading trial locations.

About this study

This research study is a Feasibility Study, which is the first-time investigators are examining this supportive care mobile app intervention. The goal of this research study is to refine and examine the feasibility and benefits of a supportive care mobile app to improve symptoms, coping skills, and quality of life in patients with non-small cell lung cancer. Many people diagnosed with lung cancer experience challenging symptoms and increased stress. To help address these concerns, this study is exploring how a mobile application (app) intervention, designed specifically for people with lung cancer, can expand the availability of much needed supportive care services.

The research study procedures include:

  • A supportive care mobile app consisting of six intervention modules that focus on components of wellbeing, such as physical, social, functional, and emotional wellbeing
  • Questionnaires asking about demographic information (e.g., gender, ethnicity, income) and participants' experience with cancer (e.g., quality of life, symptoms)
  • Data collection from participants medical records

After completing a baseline study questionnaire, participants will be randomized into two (2) study groups:

  • Usual Care Group: Participants will receive standard oncology care and attend their regular clinic visits. Study staff will monitor participant use of supportive care services.
  • Intervention Group: Participants will be provided with a study-issued tablet computer to access the mobile app and receive tutorial and instructions for how to use the app.

Participants will be in this research study for 12-14 weeks.

It is expected that about 120 people will take part in this research study.

The sponsors of this study are the National Comprehensive Cancer Network (NCCN) and AstraZeneca Pharmaceuticals. NCCN is a non-profit alliance of leading cancer centers across the United States, and AstraZeneca Pharmaceuticals is a global bio-pharmaceutical company. These two sponsors are together providing funding and oversight for the conduct of this research study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years
  • Diagnosed with unresectable Stage III or IV NSCLC in the past twelve weeks and receiving care with palliative intent (per clinician documentation in the electronic health record)
  • Eastern Cooperative Oncology Group Performance Status = 0-3
  • Plan to receive oncology care at one of the participating study sites
  • Ability to read and respond to questions in English

Exclusion criteria

  • Significant uncontrolled psychiatric disorder (e.g., psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the ability to participate in study procedures

Treatment and study plan

Supportive Care Mobile Application

Behavioral

Tablet computer with application providing modules on skills for managing symptoms and coping.

Usual Care

Other

Standard oncology care with monitoring of supportive care services usage

Primary outcomes

  1. Study feasibility based on rates of participant recruitment and completion of assigned study procedures

    Time frame: 12 weeks

    Study feasibility will be defined as ≥ 65% approach-to-enrollment rate of eligible participants and

    ≥70% completion rate of study procedures (at least four mobile app modules and assigned study questionnaires)

Secondary outcomes

  1. Patient-reported acceptability and usability of the mobile application intervention on the System Usability Scale

    Time frame: 12 weeks

    Describe patient-reported acceptability and ease of use of the mobile application intervention based on scores from the System Usability Scale (score range: 0-100; higher scores indicate greater acceptability and ease of use)

  2. Compare patient-reported quality of life between study groups on the Functional Assessment of Cancer Therapy-Lung Scale

    Time frame: 12 weeks

    Compare between study groups patient-reported quality of life based on scores from the Functional Assessment Cancer Therapy-Lung Scale at 12 weeks (score range: 0-136; higher scores indicate better quality of life)

  3. Compare patient-reported symptoms between study groups on the MD Anderson Symptom Inventory

    Time frame: 12 weeks

    Compare between study groups patient-reported symptom severity and interference based on scores from the MD Anderson Symptom Inventory at 12 weeks (score range: 0-10 on the symptom severity and interference sub-scales; higher scores indicate worse symptoms)

  4. Compare patient-reported psychological distress between study groups on the Hospital Anxiety and Depression Scale

    Time frame: 12 weeks

    Compare between study groups patient-reported anxiety and depression symptoms based on scores from the Hospital Anxiety and Depression Scale at 12 weeks (score range: 0-21 on the anxiety and depression sub-scales; higher scores indicate worse psychological distress)

  5. Compare patient-reported coping between study groups on the Brief COPE Scale

    Time frame: 12 weeks

    Compare between study groups patient-reported coping strategies based on scores from the Brief COPE Scale at 12 weeks (score range: 2-8 on each of 14 coping sub-scales; higher scores indicate greater use of that specific coping strategy)

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • National Comprehensive Cancer Network

Registry information

Official study title

Randomized Trial of a Supportive Care Mobile Application to Improve Symptoms, Coping, and Quality of Life in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Nov 16, 2020
Registry last updated
Nov 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.